Harvard Bioscience, Inc. (HBIO) vs NexGel, Inc. (NXGL)
- Harvard Bioscience, Inc. HBIO 8.09 −2.65%
- NexGel, Inc. NXGL 5.59 +7.92%
Harvard Bioscience, Inc. and NexGel, Inc. are both Medical Instruments & Supplies companies. Harvard Bioscience, Inc. is the larger, with a market value of $37.8M against $15.9M — 2.4× the size. NexGel, Inc. grew revenue faster over the last twelve months: 3.38% against −1.06%. Harvard Bioscience, Inc. has the higher net margin (−11.9% vs −51.3%) and the higher return on invested capital (−0.41% vs −45.3%). Across the 18 metrics below, Harvard Bioscience, Inc. leads on 12 and NexGel, Inc. on 6.
Valuation
Profitability
| Metric | HBIO | NXGL | Medical Instruments & Supplies median |
|---|---|---|---|
| Gross margin | 58.16% | 35.08% | 54.29% |
| Operating margin | (0.28%) | (44.77%) | 1.07% |
| Net margin | (11.86%) | (51.26%) | (1.61%) |
| Free cash flow margin | (2.09%) | (27.66%) | 1.08% |
| Return on equity | (89.95%) | (117.57%) | (1.32%) |
| Return on assets | (13.32%) | (34.21%) | 0.00% |
| Return on invested capital | (0.41%) | (45.29%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack